enGene Therapeutics Inc. (ENGN)

enGene Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is November - October.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jan 31, 2026	Oct 31, 2025	Oct 31, 2024	Oct 31, 2023	Oct 31, 2022
Net Income	-122.44	-117.3	-55.14	-99.92	-24.46
Depreciation & Amortization	0.6	0.51	0.32	0.18	0.24
Stock-Based Compensation	10.64	9.65	5.32	3.45	0.12
Other Adjustments	-1.1	-1.88	0.8	72.07	4.34
Changes in Accounts Payable	-0.45	4.94	0.47	0.37	-0.2
Changes in Accrued Expenses	11.4	3.13	5.23	0.87	2.34
Changes in Other Operating Activities	-1.14	1.67	-5.6	-1.76	0.03
Operating Cash Flow	-102.45	-99.24	-48.28	-24.74	-17.59
Capital Expenditures	-1.34	-1.49	-0.93	-0.32	-0.15
Purchases of Investments	-235.37	-160.84	-125.03	-	-
Proceeds from Sale of Investments	170.23	137.19	-	-	-
Investing Cash Flow	-66.47	-25.14	-125.95	-0.32	-0.15
Long-Term Debt Issued	25	-	22.5	38	29.4
Long-Term Debt Repaid	-23.75	-0.7	-9.45	-4.73	-1.01
Net Long-Term Debt Issued (Repaid)	1.25	-0.7	13.06	33.27	28.39
Issuance of Common Stock	152	2.22	266.25	64.3	0.01
Net Common Stock Issued (Repurchased)	152	2.22	266.25	64.3	0.01
Other Financing Activities	-10.06	-	-13.58	-11.42	-0.44
Financing Cash Flow	143.18	1.52	265.72	86.15	27.97
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0	0	0	-	-0.81
Net Cash Flow	-25.73	-122.85	91.48	61.09	9.42
Free Cash Flow	-103.79	-100.72	-49.21	-25.06	-17.75
Free Cash Flow Per Share	-1.88	-1.97	-1.30	-36.18	-27.09
Levered Free Cash Flow	-112.13	-109.24	-42.59	-72.13	1.63
Unlevered Free Cash Flow	-118.66	-114.4	-62.78	-26.72	-17.19

Updated Mar 9, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q